{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Summary Information section of this notice to Aspyrian Therapeutics, Inc. (\"Aspyrian\") located in San Diego, California USA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/09/22/2016-22820.html","cfr_references":[],"citation":"81 FR 65364","comment_url":null,"comments_close_on":"2016-10-07","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before October 7, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-22820","effective_on":null,"end_page":65365,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/09/22/2016-22820.xml","html_url":"https://www.federalregister.gov/documents/2016/09/22/2016-22820/prospective-grant-of-exclusive-patent-license-development-of-an-antibody-drug-conjugate-for-use-in","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-22820?publication_date=2016-09-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-09-22/2016-22820/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":246,"last_updated":"2026-07-26 10:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-09-22/pdf/2016-22820.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-22820.pdf?1474461953","publication_date":"2016-09-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/09/22/2016-22820.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T00:30:08Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":65364,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Development of an Antibody-Drug Conjugate for Use in PhotoImmunoTherapy","toc_doc":"Development of Antibody-drug Conjugate for Use in PhotoImmunoTherapy","toc_subject":"Proposed Exclusive Licenses:","topics":[],"type":"Notice","volume":81}